PharmAla Receives First Office Action for PharmAla-1 PCT Filing
25 sept. 2023 08h55 HE
|
PharmAla Biotech
PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty
PharmAla Begins Trading on OTCQB
06 sept. 2023 08h55 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the...
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
10 août 2023 08h30 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
31 juil. 2023 08h30 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
20 juil. 2023 09h07 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
Cortexa Makes First Drug Order for Australian Commercial Market
04 juil. 2023 08h55 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 04, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Biotech Receives Export Permit to Ship GMP LaNeo MDMA to the University of Sydney
16 juin 2023 09h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, June 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF, a biotechnology company focused on the research,...
PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000
12 juin 2023 20h07 HE
|
PharmAla Biotech
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (the...
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
09 juin 2023 15h48 HE
|
PharmAla Biotech
Approved Study to Examine Tolerability of MDMA in Schizophrenia at UCLA VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE:...
PharmAla Awarded Research Grant by Ontario Centre for Innovation
09 juin 2023 13h18 HE
|
PharmAla Biotech
TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel...